XIANYANG, China, Dec. 4, 2017 /PRNewswire/ -- Biostar
Pharmaceuticals, Inc. (NASDAQ:BSPM) ("Biostar" or "the Company"), a
PRC-based manufacturer and marketer of pharmaceutical and health
supplement products in China,
announced that on November 30, 2017,
it received a letter from the NASDAQ Listing Qualifications Staff
("Staff") notifying the Company that it regained compliance with
NASDAQ's Listing Rule 5250(c)(1) for continued listing on NASDAQ
Capital Market and the Staff considers the matter closed.
On August 22, 2017, the Company
received a Staff notification letter advising the Company that,
since it had not filed its Quarterly Report on Form 10-Q for the
fiscal year ended June 30, 2017, the
Company was not in compliance with NASDAQ Listing Rule 5250(c)(1).
Following the notification letter, the Company submitted a plan of
compliance and, upon the Staff's review of the plan, was provided
an exception until November 30, 2017 to implement its plan to
regain listing compliance. On November 15, 2017, the Company filed
the subject Quarterly Report for the fiscal quarter ended June 30,
2017.
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly owned
subsidiary and controlled affiliate in China, develops, manufactures, and markets
pharmaceutical and health supplement products for a variety of
diseases and conditions. For more information please visit:
http://www.biostarpharmaceuticals.com.
Safe Harbor Relating to the Forward-Looking
Statements
Certain statements in this release concerning our future growth
prospects are forward-looking statements, within the meaning of
Section 27A of the U.S. Securities Act of 1933, as amended, and
Section 21E of the U.S. Securities Exchange Act of 1934, as
amended, which involve a number of risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. The company uses words and phrases such
as "guidance," "forecasted," "projects," "is expected," "remain
confident," "will" and similar expressions to identify
forward-looking statements in this press release, including
forward-looking statements. Undue reliance should not be placed on
forward-looking information. Forward-looking information is based
on current expectations, estimates and projections that involve a
number of risks, which could cause actual results to vary and in
some instances to differ materially from those anticipated by
Biostar and described in the forward-looking information contained
in this news release. Risks that could affect our future operating
results are more fully described in our United States Securities
and Exchange Commission filings including our most recent Annual
Report on Form 10-K for the year ended December 31, 2016, and other subsequent public
filings. These filings are available at www.sec.gov. We may, from
time to time, make additional written and oral forward-looking
statements, including statements contained in our filings with the
Securities and Exchange Commission and our reports to shareholders.
We do not undertake to update any forward-looking statements that
may be made from time to time by or on our behalf.
Investor Relations Contact
Please send questions or comments to:
Biostar Pharmaceuticals, Inc.
Investor Relations Coordinator
+86-29-3368-6638
office@aoxing-group.com
http://www.biostarpharmaceuticals.com
View original
content:http://www.prnewswire.com/news-releases/biostar-regains-compliance-with-nasdaq-continued-listing-requirement-300565627.html
SOURCE Biostar Pharmaceuticals, Inc.